Transplantation & Cellular Therapy
The latest news, research, and perspectives in transplantation and cellular therapy. Autologous and allogeneic hematopoietic stem cell transplantation represent potentially curative options for some patients, while the field of non-transplant cellular therapies, such as chimeric antigen receptor (CAR) T-cell therapies, CAR natural killer cell therapies, and genetically modified T-cell receptors, is also expanding to offer more patients curative options.
Dr. de Lima discusses progress and remaining challenges with allogeneic CAR-T and other cellular therapy products.
Ibrutinib has a monthly sticker price of $17,000 and was taken by 20,000 people who were beneficiaries of Medicare.
Critical drugs used to treat cancer are in short supply in the United States and around the globe.
Researchers conducted the study because patients with TP53-mutated disease “have poor outcomes with standard approaches."
CART-ddBCMA is an investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma.
There was a median of two production slots per month from March 2021 to October 2021. All slots were filled.
The difference in infection rates between the treatment and placebo groups was not statistically significant.
Dr. DiPersio discusses events that shaped his career, his lab’s most transformative research, and the future of transplant.
Omidubicel-onlv is a “substantially modified” allogeneic cord blood-based cell therapy.
Dr. June has made “seminal contributions” to CAR T-cell therapy for blood cancers,
Nearly half of caregivers reported a high use of approach-oriented coping strategies.
None of the patients with DDX41 variants who received post-HSCT cyclophosphamide developed severe acute GVHD.
The overall neutrophil response rate, defined as recovery or improvement, was 84% within a median of nine days.
Dr. Pickl discusses potential future uses and implications of a novel biomarker to predict responses to CAR-T in DLBCL.
Dr. Bishop discusses the matter with host Chadi Nabhan, MD, MBA, FACP, and speaks about why CAR-T doesn't always work.
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
The study's investigators identified a four-gene model that segregated patients with different survival probabilities.
The study used natural language processing for computer-assisted review of electronic health records.
The investigators plan to continue using the monitoring strategies and further study patient outcomes.
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
The research has implications for patients with hematologic malignancies who need to undergo allogeneic HSCT.
BMS-986393, a GPRC5D-directed CAR-T, had a "favorable” safety profile with “promising” preliminary efficacy in R/R MM.
Survival outcomes are typically poor in patients with relapsed/refractory aggressive BCL who relapse after anti-CD19 CAR-T.
Post-transplant cyclophosphamide]-based GVHD prophylaxis mitigates the development of gastrointestinal GVHD.
Children with R/R B-cell ALL who received co-administered CD19-and CD22-directed CAR-T therapy had a 99% CR.
Allogeneic CAR T-cells had “encouraging safety and efficacy” in patients with CD7-positive hematologic malignancies.
Axicabtagene ciloleucel led to higher response rates and higher toxicity rates than tisagenlecleucel in R/R DLBCL.
Allogeneic off-the-shelf CAR T-cells “showed evidence of antileukemic activity” in heavily pretreated patients...
Certain genetic features in tumor and plasma samples from patients with LBCL are associated with poor CD19-directed CAR-T...
A GPRC5D-targeted CAR T-cell therapy led to a 71% response rate in patients with heavily pretreated multiple myeloma...
CD19-directed CAR T-cells led to a complete remission in around half of patients with relapsed/refractory CNS lymphoma.
Health-related quality of life improved in patients with R/R MM following treatment with the CAR T-cell treatment...
Researchers have recently identified bacterial proliferation on the skin as a factor associated with the development of...
A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients...
Dr. Lentzsch and Dr. Wong discuss the role of transplantation in newly diagnosed systemic light chain (AL) amyloidosis...
Autologous chimeric antigen receptor (CAR) T-cell therapies have shown “unprecedented efficacy” in patients with ...
Carlos de Lima, MD, stopped by the Blood Cancers Today booth at the 2022 SOHO Annual Meeting to give his advice...
A conditioning regimen of clofarabine plus total body irradiation led to a two-year overall survival rate of 43%
Researchers investigated its use in patients undergoing mismatched donor HSCT with post-transplant cyclophosphamide...
Researchers had not previously studied the long-term impact of omidubicel...
New research suggests venetoclax-containing regimens with intensive treatment and may improve outcomes.
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, provides an update...
The combination led to an overall survival rate of nearly 75% in patients with BPDCN...
First-line treatment with tagraxofusp led to an overall response rate of 75% in patients with blastic plasmacytoid...
Blood Cancers Today spoke with clinicians about the two available second-line chimeric antigen receptor T-cell therapies...
A second allogeneic HSCT is a reasonable treatment option for patients with relapsed AML.
The largest study yet comparing chimeric antigen receptor (CAR) T-cell therapy with the previous standard of care (SOC)...
In second-line therapy for relapsed/refractory LBCL, which patients would you consider eligible for CAR T-cell therapy...
The number of "chemotherapy-free" drugs and regimens grows as more is learned about the biology of hematologic malignancies.
Advances have been accomplished in the management of adults with acute lymphoblastic leukemia...
Advertisement
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
